Serum soluble CD163 and interleukin-6 levels in women with ovarian endometriomas

Jee BC, Byung Chul Jee, Suh CS, Chang Suk Suh, Seok Hyun Kim, Kim SH, Moon SY, Shin Yong Moon
Gynecologic and obstetric investigation · 2008 · vol. 66(1) , pp. 47–52 · doi:10.1159/000119091 · PMID:18311079 · W2032938986
Other OA: closed CC0 ⤵ 18 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Serum levels of soluble CD163 and interleukin-6 were evaluated in women with ovarian endometriomas and other adnexal benign cystic tumors, finding no significant differences among groups.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: CD163 is a hemoglobin scavenger receptor exclusively expressed in the monocyte-macrophage system and its soluble form (sCD163) has not yet been studied as a serum marker in women with endometriosis. The purpose of this study was to evaluate whether serum levels of sCD163 and interleukin-6 (IL-6) could be possible markers for ovarian endometriomas discriminating adnexal benign cystic tumors. METHODS: The concentrations of sCD163 and IL-6 were determined using commercial ELISA kits in frozen sera collected from 95 women prior to surgery for adnexal benign cystic tumors: 44 with ovarian endometriomas, 24 with mature cystic teratomas, 10 with mucinous cystadenomas, 8 with serous cystadenomas and 9 with parovarian cysts. Serum levels of CA-125 were also recorded preoperatively. The volume of cysts was evaluated in women with ovarian endometriomas. RESULTS: The serum levels of sCD163 and IL-6 were not significantly different among the women with various adnexal benign cystic tumors. In patients with endometriomas (n = 44), the levels were similar to those with nonendometriotic benign cystic tumors (n = 51): 3,431.7 +/- 343.9 vs. 3,231.0 +/- 391.7 ng/ml for sCD163 and 5.3 +/- 0.9 vs. 12.9 +/- 4.0 pg/ml for IL-6 (mean +/- SEM). No correlation was noted between serum levels of two markers with volume of endometriomas. CONCLUSION: Our findings suggest that serum levels of sCD163 as well as IL-6 are not useful markers for ovarian endometriomas.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antigens, CD Antigens, Differentiation, Myelomonocytic Endometriosis Interleukin-16 Ovarian Diseases Receptors, Cell Surface Adult Adult Antigens, CD Antigens, CD Antigens, Differentiation, Myelomonocytic Antigens, Differentiation, Myelomonocytic Biomarkers Biomarkers Biomarkers CA-125 Antigen CA-125 Antigen CA-125 Antigen CD163 Antigen CD163 Antigen

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (36)

Cited by (19)

Source provenance

europepmc
last seen: 2026-10-26T06:15:05.866214+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:05:10.907216+00:00
License: CC0 · commercial use OK